MX2018011453A - Moduladores alostericos de receptores de acetilcolina nicotinicos. - Google Patents

Moduladores alostericos de receptores de acetilcolina nicotinicos.

Info

Publication number
MX2018011453A
MX2018011453A MX2018011453A MX2018011453A MX2018011453A MX 2018011453 A MX2018011453 A MX 2018011453A MX 2018011453 A MX2018011453 A MX 2018011453A MX 2018011453 A MX2018011453 A MX 2018011453A MX 2018011453 A MX2018011453 A MX 2018011453A
Authority
MX
Mexico
Prior art keywords
nicotinic acetylcholine
allosteric modulators
compounds
acetylcholine receptors
disease
Prior art date
Application number
MX2018011453A
Other languages
English (en)
Inventor
M Sanders John
L Duffy Joseph
M Crowley Brendan
t campbell Brian
J Greshock Thomas
G Guiadeen Deodial
John Harvey Andrew
C Huff Belinda
J Leavitt Kenneth
L Rada Vanessa
D Shipe William
M Suen Linda
M Bell Ian
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2018011453A publication Critical patent/MX2018011453A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of El Displays (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente divulgación se refiere a compuestos de fórmula I que son útiles como moduladores de nAChR a7, a composiciones que comprenden dichos compuestos y al uso de dichos compuestos para prevenir, tratar o mejorar enfermedades, en particular trastornos del sistema nervioso central tales como alteraciones cognitivas en enfermedad de Alzheimer, la enfermedad de Parkinson y esquizofrenia, así como para disquinesia inducida por L-DOPA e inflamación. (ver Fórmula).
MX2018011453A 2016-03-22 2017-03-20 Moduladores alostericos de receptores de acetilcolina nicotinicos. MX2018011453A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662311888P 2016-03-22 2016-03-22
US201662369778P 2016-08-02 2016-08-02
PCT/US2017/023127 WO2017165256A1 (en) 2016-03-22 2017-03-20 Allosteric modulators of nicotinic acetylcholine receptors

Publications (1)

Publication Number Publication Date
MX2018011453A true MX2018011453A (es) 2019-01-10

Family

ID=58455680

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011453A MX2018011453A (es) 2016-03-22 2017-03-20 Moduladores alostericos de receptores de acetilcolina nicotinicos.

Country Status (39)

Country Link
US (3) US20190337910A1 (es)
EP (2) EP3978479A1 (es)
JP (1) JP6526352B2 (es)
KR (1) KR102203552B1 (es)
CN (1) CN109153649B (es)
AR (1) AR107928A1 (es)
AU (1) AU2017237930B2 (es)
CA (1) CA3018185C (es)
CL (1) CL2018002697A1 (es)
CO (1) CO2018009889A2 (es)
CR (1) CR20180452A (es)
CY (1) CY1124828T1 (es)
DK (1) DK3433234T3 (es)
DO (1) DOP2018000204A (es)
EC (1) ECSP18078877A (es)
ES (1) ES2901197T3 (es)
GE (1) GEP20207149B (es)
HR (1) HRP20211960T1 (es)
HU (1) HUE057460T2 (es)
IL (1) IL261807A (es)
JO (1) JOP20170067B1 (es)
LT (1) LT3433234T (es)
MA (1) MA43756B1 (es)
MD (1) MD3433234T2 (es)
MX (1) MX2018011453A (es)
MY (1) MY195948A (es)
PE (1) PE20181851A1 (es)
PH (1) PH12018502028A1 (es)
PL (1) PL3433234T3 (es)
PT (1) PT3433234T (es)
RS (1) RS62704B1 (es)
SG (1) SG11201808220VA (es)
SI (1) SI3433234T1 (es)
SV (1) SV2018005743A (es)
TN (1) TN2018000322A1 (es)
TW (1) TWI616438B (es)
UA (1) UA120571C2 (es)
WO (1) WO2017165256A1 (es)
ZA (1) ZA201806141B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578543A1 (en) 2015-04-17 2019-12-11 Dow AgroSciences LLC Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
CN118044519A (zh) 2016-10-12 2024-05-17 科迪华农业科技有限责任公司 具有杀虫效用的分子、以及与其相关的中间体、组合物和方法
WO2018085171A1 (en) * 2016-11-01 2018-05-11 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2019000238A1 (en) * 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
CA3073212A1 (en) 2017-09-19 2019-03-28 Merck Sharp & Dohme Corp. Heteroaryl allosteric modulators of nicotinic acetylcholine receptors
CA3098583C (en) * 2018-05-01 2023-05-16 Merck Sharp & Dohme Corp. Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
HU231414B1 (hu) * 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
HU231333B1 (hu) * 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
TW202039420A (zh) * 2018-11-26 2020-11-01 美商富曼西公司 用於防治無脊椎害蟲的間二醯胺化合物
US20220119351A1 (en) * 2019-05-02 2022-04-21 Merck Sharp & Dohme Corp. Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
WO2021091751A1 (en) * 2019-11-05 2021-05-14 Merck Sharp & Dohme Corp. Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
CN111233783B (zh) * 2020-03-13 2021-11-16 温州大学 异噻唑-4-基二硫化物衍生物的合成方法
WO2023049058A1 (en) * 2021-09-21 2023-03-30 Merck Sharp & Dohme Llc Allosteric modulators of nicotinic acetylcholine receptors
CA3235444A1 (en) * 2021-10-12 2023-04-20 Brown University Glioblastoma multiforme treatments

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3487154A (en) 1967-04-03 1969-12-30 Smithkline Corp Method of lowering blood pressure
US3522302A (en) 1967-05-16 1970-07-28 Smithkline Corp P-(2-aminocycloalkyl)benzenesulfonamides
FR2508033A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Aryl-1 aminomethyl-2 cyclopropanes carboxylates (z), leur preparation et leur application en tant que medicaments utiles dans le traitement d'algies diverses
US5286736A (en) 1990-11-22 1994-02-15 Dr. Karl Thomae Gmbh Pyridyl compounds and pharmaceutical compositions containing these compounds
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
FR2751645B1 (fr) 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
AR017014A1 (es) 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
TR200002380T2 (tr) 1998-02-17 2001-03-21 Astrazeneca Uk Limited Yeni triazolo (4,5-d) pirimidin bileşikleri
SE9802574D0 (sv) 1998-07-17 1998-07-17 Astra Pharma Prod Novel compounds
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
WO2001055146A1 (en) 2000-01-29 2001-08-02 Lg Chem Investment Ltd. FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF
US6630469B2 (en) 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
FR2810664B1 (fr) * 2000-06-27 2004-12-24 Adir Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002079152A1 (en) 2001-03-29 2002-10-10 Bristol-Myers Squibb Company Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
US7423067B2 (en) 2002-03-26 2008-09-09 Merck & Co., Inc. Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
ATE506354T1 (de) 2003-01-06 2011-05-15 Lilly Co Eli Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
JP2008525524A (ja) * 2004-12-28 2008-07-17 アストラゼネカ・アクチエボラーグ アリールスルホンアミドモジュレーター
EP1934237A2 (en) * 2005-08-24 2008-06-25 Rib-X Pharmaceuticals, Inc. Triazole compounds and methods of making and using the same
CN102058571B (zh) 2005-09-09 2012-09-19 有限会社肯菲思 4-[(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基甲酰基]苯甲酸在制备用于预防及/或治疗肠疾病的药物中的应用
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
CN101903338A (zh) 2007-12-19 2010-12-01 安姆根有限公司 用作炎症调节剂的苯基乙酸衍生物
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
BRPI0917803A2 (pt) 2008-08-12 2019-09-03 Hoffmann La Roche derivados de salicilamida como moduladores nicotínicos alfa 7
EP2379525B1 (en) 2008-12-19 2015-07-29 Boehringer Ingelheim International GmbH Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
EP2337781B1 (en) 2009-06-11 2014-07-23 AbbVie Bahamas Ltd. Anti-viral compounds to treat hcv infection
WO2010144959A1 (en) 2009-06-18 2010-12-23 Fibrotech Therapeutics Pty Ltd Analogues of anti-fibrotic agents
WO2011019538A1 (en) * 2009-08-13 2011-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012012410A2 (en) 2010-07-19 2012-01-26 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
JP2013540767A (ja) 2010-10-07 2013-11-07 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 免疫不全ウイルス転写を調節するための組成物および方法
JP5906253B2 (ja) 2010-12-16 2016-04-20 アッヴィ・インコーポレイテッド 抗ウイルス性化合物
KR101925971B1 (ko) 2011-01-28 2018-12-06 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
US9062013B2 (en) 2011-02-02 2015-06-23 Bionomics Limited Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof
CA2826792A1 (en) 2011-02-23 2012-08-30 Lupin Limited Heteroaryl derivatives as alpha7 nachr modulators
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US8946432B2 (en) 2011-07-05 2015-02-03 Lupin Limited Biaryl derivatives as nAChR modulators
UA111746C2 (uk) * 2011-07-08 2016-06-10 Х. Луннбек А/С Позитивні алостеричні модулятори нікотинового рецептора ацетилхоліну
US8598213B2 (en) 2011-07-08 2013-12-03 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
CA2844469C (en) 2011-08-08 2019-08-20 Merck Patent Gmbh N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists
WO2014006120A1 (en) 2012-07-06 2014-01-09 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
JP2015529651A (ja) * 2012-08-01 2015-10-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． α７ニコチン性アセチルコリン受容体モジュレーターおよびそれらの使用−Ｉ
EP2928860A1 (en) 2012-12-10 2015-10-14 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
MX368258B (es) 2013-03-15 2019-09-25 Zymeworks Inc Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos.
WO2014172759A1 (en) 2013-04-24 2014-10-30 Bionomics Limited α7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF - III
TW201446243A (zh) * 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
CN106459162A (zh) 2013-12-27 2017-02-22 酵活有限公司 Var2csa‑药物偶联物
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
AU2015268961B9 (en) 2014-06-04 2019-10-10 Thomas Helledays Stiftelse For Medicinsk Forskning MTH1 inhibitors for treatment of cancer
SG11201609981RA (en) 2014-06-04 2016-12-29 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
EP3154537B1 (en) * 2014-06-13 2020-01-01 Merck Sharp & Dohme Corp. Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof

Also Published As

Publication number Publication date
CA3018185A1 (en) 2017-09-28
CN109153649A (zh) 2019-01-04
KR102203552B1 (ko) 2021-01-18
EP3433234B1 (en) 2021-10-27
SG11201808220VA (en) 2018-10-30
ECSP18078877A (es) 2019-02-28
TWI616438B (zh) 2018-03-01
US9926285B2 (en) 2018-03-27
AU2017237930A1 (en) 2018-10-11
MY195948A (en) 2023-02-27
UA120571C2 (uk) 2019-12-26
JP6526352B2 (ja) 2019-06-05
PL3433234T3 (pl) 2022-01-24
CL2018002697A1 (es) 2018-12-28
DK3433234T3 (da) 2022-01-03
TN2018000322A1 (en) 2020-01-16
CO2018009889A2 (es) 2018-10-22
PH12018502028A1 (en) 2019-07-15
SV2018005743A (es) 2019-01-18
JP2019512508A (ja) 2019-05-16
CA3018185C (en) 2020-09-15
KR20180127644A (ko) 2018-11-29
SI3433234T1 (sl) 2022-01-31
ZA201806141B (en) 2019-08-28
CR20180452A (es) 2019-02-06
RS62704B1 (sr) 2022-01-31
IL261807A (en) 2018-10-31
GEP20207149B (en) 2020-09-10
US20170275260A1 (en) 2017-09-28
MA43756A (fr) 2021-05-19
LT3433234T (lt) 2021-12-10
PE20181851A1 (es) 2018-12-03
MD3433234T2 (ro) 2022-02-28
MA43756B1 (fr) 2021-11-30
US20190337910A1 (en) 2019-11-07
WO2017165256A1 (en) 2017-09-28
CY1124828T1 (el) 2022-11-25
CN109153649B (zh) 2022-04-19
DOP2018000204A (es) 2019-07-15
HRP20211960T1 (hr) 2022-03-18
EP3978479A1 (en) 2022-04-06
US9840481B2 (en) 2017-12-12
PT3433234T (pt) 2021-12-22
US20180030007A1 (en) 2018-02-01
EP3433234A1 (en) 2019-01-30
JOP20170067B1 (ar) 2021-08-17
ES2901197T3 (es) 2022-03-21
AU2017237930B2 (en) 2019-02-07
TW201733989A (zh) 2017-10-01
HUE057460T2 (hu) 2022-05-28
AR107928A1 (es) 2018-06-28
BR112018069456A2 (pt) 2019-02-05

Similar Documents

Publication Publication Date Title
PH12018502028A1 (en) Allosteric modulators of nicotinic acetylcholine receptors
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
PH12020551779A1 (en) Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
TW201613890A (en) Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators
PH12017501043A1 (en) 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
PH12019500196A1 (en) Compounds and compositions and uses thereof
MX368459B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
PH12019500198A1 (en) Compounds and compositions and uses thereof
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2017001603A (es) Derivados de piperazina como moduladores de los receptores x del higado.
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
JO3367B1 (ar) مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX2019002125A (es) Derivados de hidroxinorketamina para el tratamiento de trastornos.
EA201892113A1 (ru) Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов
MX2017008639A (es) Derivados de heterociclilalquino y su uso como moduladores de los receptores mglur5.

Legal Events

Date Code Title Description
FG Grant or registration